Abstracts tagged "Biologicals"

Abstract Number: 1674 • ACR Convergence 2023
Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group
Benjamin de Valence de Minardiere¹, Marion Delaune², Yann Nguyen³, Vincent Jachiet⁴, Mael Heiblig⁵, Alexis Jean⁶, Pierrick Henneton⁷, stanislas Riescher-tuczkiewicz⁸, Philippe Guilpain⁷, Hervé Lobbes⁹, Guillaume Le Guenno¹⁰, Nicolas Schleinitz¹¹, Valentin Lacombe¹², Vincent Langlois¹³, Roderau Outh¹⁴, Julien Vinit¹⁵, Jean-Philippe Martellosio¹⁶, Paul Decker¹⁷, Alexandre Vlakos¹⁸, Thomas Moulinet¹⁹, Yannick Dieudonne²⁰, Adrien Bigot²¹, Louis Terriou²², Bertrand De Maleprade²³, Guillaume Denis²⁴, Jonathan Broner²⁵, Marie Kostine²⁶, Sébastien Humbert²⁷, Benjamin Terrier²⁸, Sophie Georgin-Lavialle²⁹, Olivier Fain³⁰, Arsène Mekinian¹, Marjolaine MORGAND¹, Thibault Comont² and Jerome Hadjadj¹, ¹Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ²Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ⁴Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France, ⁵Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France, ⁶Internal Medicine Department, Bordeaux University, Faculty of Medicine, Bordeaux University Hospital, Bordeaux, France, ⁷CHU Montpellier, Montpellier, France, ⁸CHU de Nantes, Nantes, France, ⁹CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁰Internal Medicine Department, Clermont-Ferrand University, Faculty of Medicine, Estaing University Hospital, Clermont-Ferrand, France, ¹¹Aix Marseille university, AP-HM, Marseille, France, ¹²Internal Medicine Department, Anger Hospital, Clermont-Ferrand, France, ¹³Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France, ¹⁴Internal Medicine Department, Perpignan Hospital Center, Perpignan, France, ¹⁵Service de Médecine Interne, CH William Morey, Chalon sur Saône, France., Chalon sur Saône, France, ¹⁶Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, ¹⁷Nancy hospital, France, Nancy, France, ¹⁸Vesoul Hospital, Vesoul, France, ¹⁹Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ²⁰Department of Clinical Immunology and Internal Medicine, National Reference Centre for Systemic Autoimmune Diseases (CNR RESO), Strasbourg University Hospital, Strasbourg, France, ²¹Internal Medicine Department, Tours University, Faculty of Medicine, Tours University Hospital, Tours, France, ²²Service de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France, ²³Rouen hospital, France, Rouen, France, ²⁴Service d'hématologie, CH de Rochefort, Rochefort, France, ²⁵CHU de Nimes, Nimes, France, ²⁶Bordeaux University Hospital, Bordeaux, France, ²⁷Besançon University Hospital, Besançon, France, ²⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²⁹AP-HP, Tenon hospital, Paris, France, ³⁰Hopital SAINT ANTOINE APHP, Paris, France
Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…
Abstract Number: 2133 • ACR Convergence 2023
Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI
Samar Aboulenain¹, Xiuying Li², Mohammad Movahedi³, Claire Bombardier¹ and Bindee Kuriya¹, ¹University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Cardiovascular (CVD) comorbidity can impact overall RA care. We demonstrated that CVD risk factors were associated with higher disease activity and disability. Here, we…
Abstract Number: 2232 • ACR Convergence 2023
Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Dennis McGonagle¹, raja atreya², Maria Abreu³, James Krueger⁴, Kilian Eyerich⁵, Robert Bissonnette⁶, Kacey Sachen⁷, Carrie Greving⁷, Brian Stoveken⁸, Deepa Hammaker⁷, Kristin Leppard⁸, John Hartman⁸, Phuc Bao⁷, Eilyn Lacy⁸, Indra Sarabia⁷, Janise Deming⁷, Matthew Duprie⁸, Joseph Brown⁷, Christopher T Ritchlin⁹, Iain McInnes¹⁰, Matthieu Allez¹¹ and Anne Fourie⁷, ¹Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ²Erlangen University Hospital, Friedrich-Alexander-Univrsität Erlangen-Nürnberg, Erlangen, Germany, ³University of Miami, Leonard Miller School of Medicine, Miami, FL, ⁴The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, ⁵Medical Center, University of Freiburg; Karolinska Institute, Department of Medicine - Division of Dermatology and Venereology, Stockholm, Sweden, ⁶Innovaderm Research Inc, Medical Director, Montréal, QC, Canada, ⁷Janssen Research and Development, LLC, Immunology, San Diego, CA, ⁸Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁹University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Hôpital Saint-Louis, Université Paris Cité, Paris, France
Background/Purpose: Monoclonal antibodies (mAbs) targeting the interleukin (IL)-23p19 subunit are effective in treating psoriatic disease; however, their molecular attributes may translate to differences in clinical…
Abstract Number: 2348 • ACR Convergence 2023
Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Jinoos Yazdany¹, Kenji Oku², Luciana Seguro³, Paula Curtis⁴, Yoshifumi Inagaki⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ²Kitasato University School of Medicine, Department of Rheumatology and Infectious Diseases, Kanagawa, Japan, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Rheumatology Division, Universidade de Sao Paulo, São Paulo, Brazil, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Brentford, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Rheumatology Unit, Department of Medicine, Padova, Italy
Background/Purpose: BEL-treated patients (pts) in clinical trials and long-term extension (LTE) studies1-7 experienced comparable incidence of infections versus those treated with standard therapy (ST) alone…
Abstract Number: 2564 • ACR Convergence 2023
The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial
Jennifer Hanberg¹, Xiaoqing Fu¹, Xiaosong Wang², Naomi Patel¹, Yumeko Kawano², Abigail Schiff², Emily Kowalski², Claire Cook¹, Kathleen Vanni², Krishan Guzzo¹, Grace Qian², Katarina Bade³, Alene Saavedra², Rathnam Venkat², Shruthi Srivatsan¹, Yuqing Zhang⁴, Jeffrey Sparks⁵ and Zachary Wallace⁶, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Many patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulators have blunted humoral responses to COVID-19 vaccines. As such, the initial mRNA vaccine series…
Abstract Number: 0089 • ACR Convergence 2023
Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases
Daniel Patton, Meghan Maurer, Nadine Morgan, Minh Pham, Daniel Boster, Justin Huard, Cathy Tan, Rachael Fasnacht, Monica Childs, Gleda Hermansky, Alex Chen, Susan Julien, Jennifer Gardell, Cathy McMahan, Courtney Crane and Kristine Swiderek, Mozart Therapeutics, Seattle, WA
Background/Purpose: In healthy individuals, CD8 Treg activation leads to selective elimination of aberrantly activated self-reactive CD4 T cells to maintain immune balance. The CD8 Treg…
Abstract Number: 0404 • ACR Convergence 2023
Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Carmen Roseman, Johan Karlsson Wallman, Jon Einarsson, Elisabeth Mogard, Elisabet Lindqvist, Meliha Kapetanovic and Tor Olofsson, Lund University and Skåne University Hospital, Lund, Sweden
Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…
Abstract Number: 0533 • ACR Convergence 2023
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
Francesco Natalucci¹, Pauline KRUG², Angela DE SOUSA LEITE², Tatiana Sokolova³, Patrick Durez⁴, Maria S. Stoenoiu² and Adrien NZEUSSEU TOUKAP⁵, ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴UCLouvain, Brussels, Belgium, ⁵Cliniques universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (axSpA) patients have shown that remission in axSpA (including nonradiographic axSpA) patients treated without b/tsDMARDs (TNFα blockers,…
Abstract Number: 0694 • ACR Convergence 2023
Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study
Lucas Maisonobe¹, Anne-Sophie Korganow², Alvise Berti³, Alban DEROUX⁴, Nicolas Dupin⁵, Selim Aractingi⁵, Giacomo Emmi⁶, Frédéric Vandergheynst⁷, Marc Fabre⁸, Nicolas Kluger⁹, Marielle Roux⁸, Noemie Abisror¹⁰, Audrey Benyamine¹¹, Giulia Cassone¹², Francois Chasset¹³, Marie-Sylvie Doutre¹⁴, Aurelie Foucher¹⁵, Caroline Freguin¹⁶, Delphine Gobert¹⁷, Yannick Gombeir⁷, José Hernandez-Rodriguez¹⁸, Noémie Legouellec¹⁹, Anne-Lise Pinault²⁰, Dimitri Titeca-Beauport²¹, Marie Jachiet²² and Benjamin Terrier²³, ¹Assistance Publique - Hopitaux de Paris, Paris, France, ²Strasbourg University Hospital, Strasbourg, France, ³University of Trento, Rochester, MN, ⁴CHU de Grenoble, Grenoble, France, ⁵CHU Cochin, Paris, France, ⁶University of Florence, Florence, Italy, ⁷Université Libre de Bruxelles, Bruxelles, Belgium, ⁸Centre Hospitalier Pierre Oudot, Bourgoin Jallieu, France, ⁹Helsinki University Central Hospital, Helsinki, Finland, ¹⁰Internal Medicine Saint Antoine Hospital, Paris, France, ¹¹Hopital Nord Marseille, Marseille, France, ¹²Universita degli Studi di Modena e Reggio, Modena, Italy, ¹³Dermatology Department, Tenon Hospital, Paris, France, ¹⁴CHU Bordeaux, Bordeaux, France, ¹⁵CHU de la Réunion, Saint pierre, France, ¹⁶Centre Hospitalier Saint-Brieuc, Saint Brieux, France, ¹⁷CHU Sant-Atoine, Paris, France, ¹⁸Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁹Centre Hospitalier de Valenciennes, Valenciennes, France, ²⁰Centre Hospitalier Epinal, Epinal, France, ²¹CHU Amiens, Amiens, France, ²²CHU Saint-Louis, Paris, France, ²³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Urticarial vasculitis (UV) is characterized by atypical urticarial lesions and leukocytoclastic vasculitis, sometimes with extra-cutaneous manifestations. First-line treatment is often based on colchicine, hydroxychloroquine,…
Abstract Number: 1064 • ACR Convergence 2023
Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination
Ryan Wilson¹, Junaid Awan², Mary Brady², Ciara Hunt², Fahd Adeeb³ and alexander fraser⁴, ¹University of Limerick, Buncrana, Ireland, ²University of Limerick, Limerick, Ireland, ³RCSI & UCD (Ireland) Malaysia Campus (RUMC), Malaysia, Malaysia, ⁴HSE, Limerick, Ireland
Background/Purpose: COVID-19 has increased the mortality rates among rheumatic patients, mainly those immunocompromised or with underlying comorbidities. During the COVID-19 vaccine development, patients on immunomodulatory…
Abstract Number: 1315 • ACR Convergence 2023
Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies
Elena Zonova¹, Antonio Abbate², Eugen Feist³, Sergey Yakushin⁴, Maria Lemak⁵, Alina Egorova⁵, Daria Bukhanova⁵, Sergey Grishin⁵, Sofia Kuzkina⁵, Mikhail Samsonov⁶ and EVGENY NASONOV⁷, ¹Novosibirsk State Medical University, Novosibirsk, Russia, ²Robert M. Berne Cardiovascular Research Center, Charlottesville, VA, ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁴Ryazan State Medical University, Ryazan, Russia, ⁵R-Pharm, Moscow, Russia, ⁶RPharm, Moscow, Russia, ⁷Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Active rheumatoid arthritis (RA) is associated with a higher prevalence of insulin resistance (IR). Dysregulation of adipokines driven by low-level systemic inflammation plays a…
Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 1675 • ACR Convergence 2023
Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei², Chi-Fang Wu², Hui Zhao², Suja Rajan³, Heather Lin² and Sharon Giordano², ¹MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX
Background/Purpose: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and concomitant cancer. Few studies…
Abstract Number: 2146 • ACR Convergence 2023
After JAK Inhibitor Failure, “Switching” or “Cycling”?
Pablo Francisco Muñoz Martínez¹, Laura Mas Sanchez², Elena Grau Garcia³, Carmen Riesco Barcena³, Anderson Victor Huaylla Quispe³, Alba Maria Torrat Noves³, Daniel Ramos Castro³, Belen Villanueva Mañez³, Iago Alcantara Alvarez³, Samuel Leal Rodriguez³, Elvira Vicens Bernabeu³, Jose Eloy Oller Rodriguez³, Ines Canovas Olmos³, Ernesto Tovar Sugrañes³, Carmen Najera Herranz³, Isabel Martinez Cordellat³, Hikmat Charia³, Rosa Negueroles Albuixech³, Marta De la Rubia Navarro², Luis Gonzalez Puig³, Jose Ivorra Cortes³ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Sagunto, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: The appearance of JAK inhibitors (JAKi) in the last few years has proved a great clinical application in rheumatic pathology and it has become…
Abstract Number: 2233 • ACR Convergence 2023
Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
Thomas Macleod¹, Xenofon Baraliakos², Emmanouil Rampakakis³, Warner Chen⁴, Antonius Pieter J Van Den Heuvel⁴, Loqmane Seridi⁴, May Shawi⁵, Frederic Lavie⁶, Joseph F. Merola⁷, Proton Rahman⁸ and Dennis McGonagle⁹, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Translational Sciences, Janssen Research & Development, LLC, Spring House, PA, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁹Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Neutrophils have potential pathogenic roles in chronic inflammatory diseases (e.g., neutrophilic cutaneous microabscesses in psoriasis, and neutrophils in the synovial fluid/tissue in PsA and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].